News
FOLD
--
0.00%
--
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (...
GlobeNewswire · 4d ago
Those who invested in Amicus Therapeutics (NASDAQ:FOLD) five years ago are up 43%
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...
Simply Wall St. · 09/16 12:12
Insider Sell: Amicus Therapeutics
MT Newswires · 09/08 11:42
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Zacks · 08/09 16:43
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
Zacks.com · 08/06 16:24
UPDATE 2-U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease
reuters.com · 08/06 15:07
Amicus Therapeutics Q2 Net Loss Narrows, Product Sales Gain
MT Newswires · 08/05 13:05
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/05 12:35
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
2Q21 Total Galafold (migalastat) Revenue of $77.4M, a 24% increase over 2Q20
GlobeNewswire · 08/05 11:00
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 ...
GlobeNewswire · 08/04 11:00
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
Benzinga · 08/02 12:50
EC approves Amicus Therapeutics' Galafold for adolescents with Fabry disease
Amicus Therapeutics (NASDAQ:FOLD) perks up 3.6% premarket after announcing that the European Commission (EC) has approved Galafold (migalastat) for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with a confirmed
Seekingalpha · 08/02 11:46
BRIEF-Amicus Therapeutics Announces European Commission Approval Of Galafold® (Migalastat) For Adolescents With Fabry Disease
reuters.com · 08/02 11:23
--Chardan Suspends Coverage on Akero Therapeutics at Neutral Rating With $12.50 Price Target
MT Newswires · 08/02 11:14
Amicus Therapeutics Announces European Commission Approval of Galafold(R) (migalastat) for Adolescents with Fabry Disease
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold (migalastat) for use in ...
GlobeNewswire · 08/02 11:00
Amicus Therapeutics Gains EU OK for Galafold for Adolescents With Fabry Disease
MT Newswires · 08/02 09:00
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 19:05
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.
GlobeNewswire · 07/27 11:00
Amicus earns a new bull at BTIG on prospects of Pompe disease candidate
Hailshadow/iStock via Getty Images Citing expert opinion on the company’s experimental therapy for Pompe disease, BTIG has assumed a buy rating on Amicus Therapeutics ([[FOLD]] +0.3%). In February, the company
Seekingalpha · 07/19 14:29
Insider Trends: 90-Days of Insider Buying at Amicus Therapeutics Eased Back with Share Disposition
MT Newswires · 07/14 21:26
Webull provides a variety of real-time FOLD stock news. You can receive the latest news about Amicus through multiple platforms. This information may help you make smarter investment decisions.
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.